



*NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO
OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA*

**OCTOPLUS SUCCESSFULLY COMPLETES EQUITY OFFERING WITH
GROSS PROCEEDS OF €4 MILLION**

Leiden, the Netherlands, 26 October 2011 – Further to its press release of 25 October 2011, OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), announces today that it has successfully completed an equity raising with € 4 million gross proceeds through a private placement of 8 million shares at an offer price of € 0.50 per share with new and existing investors.

In the context of the Offering 8 million new ordinary shares with a nominal value of € 0.12 will be issued and following such issue, the Company will have 44.778.974 shares in issue. The Company's CEO Mr. Jan Hendrik Egberts purchased 300.000 shares in the Offering.

Petercam acted as sole lead manager and placement agent in relation to the Offering. Settlement of the Offering is expected to take place on Monday 31 October 2011.

OctoPlus intends to use the proceeds of the private placement for working capital purposes and to retain upside by co-investing along with clients in selected high-value projects in the area of specialty generics.

Jan Egberts, CEO of OctoPlus, says: *“We are very happy with this additional support from both existing and new investors as well as the continued support from our founder, Joost Holthuis. The proceeds of this financing will strengthen our balance sheet and enable us to act on investment opportunities in the area of specialty generics”.*

Contact

For further information about OctoPlus and the Offering, please contact Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071 or send an e-mail to Investor Relations at IR@octoplus.nl.

About OctoPlus

OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on our proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics.

Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to U.S. persons. This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction.

The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or to or for the account of U.S. persons (as such term is defined in Regulation S under the Securities Act) or transaction not subject to, the registration requirements of the Securities Act.

In connection with the admission of the shares in the capital of the Company to trading on NYSE Euronext in Amsterdam, a prospectus will be made generally available in due course. Copies of the Prospectus will be available at no cost through the website of Euronext Amsterdam (Dutch residents only) and the website of the Company.

The clinically most advanced product incorporating our technology is Locteron[®], a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and has recently completed Phase IIb clinical studies with superior clinical data versus current treatment.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

This announcement is not an offer to sell or a solicitation of any offer to buy the securities of OctoPlus (the "Securities") in the United States or in any other jurisdiction.

The shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or an exemption from such registration is available. No public offering of Securities of OctoPlus is being made in the United States.

This announcement does not constitute a prospectus. When made generally available, copies of the prospectus may be obtained at no cost through the website of Euronext Amsterdam (Dutch residents only) and the website of OctoPlus.

This document may contain certain forward-looking statements relating to the business, financial performance and results of the Company and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to U.S. persons. This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction.

The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or to or for the account of U.S. persons (as such term is defined in Regulation S under the Securities Act) or transaction not subject to, the registration requirements of the Securities Act.

In connection with the admission of the shares in the capital of the Company to trading on NYSE Euronext in Amsterdam, a prospectus will be made generally available in due course. Copies of the Prospectus will be available at no cost through the website of Euronext Amsterdam (Dutch residents only) and the website of the Company.